Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program
This article was originally published in The Pink Sheet Daily
The Reagan-Udall Foundation has established an organizing committee to help inform the design and structure of what its Innovation in Medical Evidence Development and Surveillance program’s post-market research methods should look like and develop the IMEDS charter.
You may also be interested in...
A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.
Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.